Pharmaceutical Market Europe • Septembe 2021 • 50-52
APPOINTMENTS
Lilly UK
LAURA STEELE
Lilly UK has announced the appointment of Laura Steele as president and general manager for the UK, Ireland and Northern Europe, succeeding Ashley Diaz-Granados, who assumes a senior role within Lilly USA leading the company’s Immunology division. Steele will lead Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience. She has been with Lilly for 18 years and joins from its Corporate Business Development division, where she specialised in innovation partnerships, large-scale projects in M&A, investments and joint ventures. Steele has built a reputation for driving innovation and patient-centricity and is a global champion of diversity and inclusion within the company, passionate about overcoming inequalities and building high-performing teams. Under her leadership, Lilly will continue to work to deliver innovative medicines to patients with the ambition to launch at least 20 medicines in the ten years from 2014-2023.
NHS England
AMANDA PRITCHARD
NHS England has announced the appointment of Amanda Pritchard as chief executive officer. Pritchard was previously the NHS’ chief operating officer and has held a number of NHS management positions during her career, including chief executive of Guy’s and St Thomas’ NHS Foundation Trust, London and deputy chief executive at Chelsea and Westminster NHS Foundation Trust.
Genomics England
MATT BROWN
Genomics England has appointed Matt Brown as Chief Scientific Officer. Brown is currently Professor of Medicine at King’s College London and Director of the NIHR Biomedical Research Centre at Guy’s and St Thomas’. Previously he was Director of Genomics at the Queensland University of Technology. He also established the Australian Translational Genomics Centre.
Pfizer
CHRISTOPHER STEVO
Pfizer has announced the appointment of Christopher Stevo as senior vice president and chief investor relations officer. Stevo has more than 20 years’ experience in healthcare investing, most recently serving as head of investor relations for Alexion Pharmaceuticals. Prior to this he was senior equity analyst for Amundi US, and held numerous leadership roles with Putnam Investments.
Moderna
KATE CRONIN
Moderna has appointed Kate Cronin as Chief Brand Officer where she will serve on its Executive Committee. Cronin joins Moderna from Ogilvy Health where she served as Global CEO. Prior to her role as CEO, she held numerous leadership roles within Ogilvy, most recently as US co-president. Before joining Ogilvy, Cronin was a partner at Porter Novelli.
Ixaka
LAURENT AUDOLY
Ixaka has announced the appointment of Laurent Audoly as a non-executive director to work with the Board and leadership team. Audoly is co-founder, CEO and chairman of Parthenon Therapeutics. Previously he was CEO of Kymera and head of R&D at Pierre Fabre Pharmaceuticals, as well as holding scientific and business leadership positions at Pfizer, Merck and Pieris.
Amgen
OMAR ISHRAK
Amgen has announced the appointment of Omar Ishrak to its Board of Directors, joining from Medtronic after roles with GE Healthcare. Ishrak is board chairman of Intel and Compute Health Acquisition Corporation, and serves with the Cleveland Clinic Board, the Board of Trustees of the Asia Society and is a senior advisor to Blackstone Life Sciences.
Theragnostics
DENNIS LANGER
Theragnostics has appointed Dennis Langer to its Board as a non-executive director. Langer has an extensive pharmaceutical company background, having previously served with Neose Technologies and GlaxoSmithKline. He is currently a Director of the Whitehead Institute for Biomedical Research, Myriad Genetics and Brooklyn ImmunoTherapeutics.
Theragnostics
KEN HERRMANN
Theragnostics has also appointed Ken Herrmann of University Hospital Essen as a non-executive director to its Board. Herrmann was previously with the University of California Los Angeles and University Hospital Würzburg. He is currently chair of the EANM Oncology & Theragnostics committee, section editor of the Journal of Nuclear Medicine and on the board of Sofie Biosciences.
Sanofi
ROY PAPATHEODOROU
Sanofi has announced the appointment of Roy Papatheodorou as executive vice president, general counsel & head of Legal, Ethics & Business Integrity. Papatheodorou is currently general counsel of Novartis and will join Sanofi on 1 February 2022. He brings a wealth of experience in leading global teams. and was previously general counsel of the Actavis Group.
Sanofi
BRENDAN O’CALLAGHAN
Sanofi has also appointed Brendan O’Callaghan as executive vice president and global head of Industrial Affairs. O’Callaghan is currently Sanofi’s global head of its Biologics Platform and the Industrial Affairs head of its Specialty Care portfolio. He was previously Head of Biologics at Merck and later Vice President of its EMEA Operations, after working at Schering-Plough.
Eisai
JANNA HUTZ
Eisai has announced the appointment of Janna Hutz, as President of the Eisai Center for Genetics Guided Dementia Discovery. In this role, she will oversee the Cambridge, Massachusetts-based research centre’s work on novel immunotherapies for dementia. Prior to joining Eisai, Hutz was with Pfizer, following a move from the Novartis Institutes for Biomedical Research.
Prescient
GERALD DUNSTAN
Prescient has announced the appointment of Gerald Dunstan as Chief Strategy Officer to lead the shaping and execution of its growth plan. Dunstan has over 20 years’ experience in the healthcare and life sciences sectors including leading practices at McKinsey and KPMG, which followed several years working across drug discovery and development in Europe and North America.
Allogene Therapeutics
ELIZABETH BARRETT
Allogene Therapeutics has announced the appointment of Elizabeth Barrett to its Board of Directors. Barrett is currently the president and CEO of UroGen Pharma, and serves on the Board of Directors of Sage Therapeutics. Prior to this she was CEO of Novartis Oncology, before which she held several leadership positions at Pfizer, Cephalon and Johnson & Johnson.
Allogene Therapeutics
VICKI SATO
Allogene Therapeutics has also appointed Vicki Sato to its Board. Sato is currently on the Board of Directors at Denali Therapeutics, Vir Biotechnology and Akouos. Previously she was president of Vertex Pharmaceuticals, and vice president of research at Biogen, also serving as a member of the Biogen Scientific Advisory Board. Sato began her career in academia.
RareCan
ANITA COOPER
RareCan has announced the appointment of Anita Cooper as non-executive director, strengthening the board’s scientific and pharmaceutical experience. Cooper has over 30 years’ global experience across diverse operations and skill levels, including strategy development. She is currently a non-executive director for Simbec-Orion, which she joined from Parexel.
Qureight
CAROLINE AUSTIN
Cambridge-based clinical analytics company Qureight has announced the appointment of its first non-executive director as it embarks on a new phase of growth. Caroline Austin is the vice-president and head of business development transactions at AstraZeneca, having been with the company for over 20 years in R&D and various strategic partnering and business development positions.
Sanofi
VIVIANE MONGES
Sanofi has announced the appointment of Viviane Monges as an independent non-executive chair of the Supervisory Board of EUROAPI. Monges has many years’ experience in pharmaceuticals, with leading roles at Idorsia, Nestlé, Galderma, Novartis and Wyeth, and also worked with Agence France-Presse. She is currently an independent director at UCB and Novo Holdings.
SynOx Therapeutics
AXEL MESCHEDER
SynOx Therapeutics, the Dublin, Ireland-based, late-stage clinical biopharmaceutical company, has appointed Axel Mescheder as Chief Medical Officer. Mescheder has over 25 years' clinical development and regulatory experience in biotechnology and pharmaceutical companies, including Hoffmann-La Roche and MorphoSys, where he held a range of senior leadership positions.
SynOx Therapeutics
BROES NAEYE
SynOx Therapeutics has further strengthened its senior management team with the appointment of Broes Naeye as Chief Technology Officer. Naeye has more than 10 years’ experience in development of biopharmaceuticals, most recently serving as Global Product Supply Lead at Sanofi. Previously, he was Head of Commercial Supply and CMC Project Lead at Ablynx.
Abacus Medicine
MICHALA FISCHER-HANSEN
Abacus Medicine has strengthened its Board with the appointment of Michala Fischer-Hansen. She brings significant pharma industry and commercial experience and is currently executive vice president at Falck, after 19 years with Novo Nordisk. Previously she served as vice chairman of the Board of the World Diabetes Foundation and was a member of the Board of Medicines Australia.
Healthware Group
GIOVANNI LORIA
Healthware Group has appointed Giovanni Loria as Chief Financial Officer. Loria will be responsible for overall financial management, driving long-term business and strategic growth, supporting the company in its future evolution. Previously he held senior roles with Cisco Systems, Dell Technologies and Alcatel-Lucent, and was a strategic advisor to digital start-ups.
Aurora
SEBASTIAN STOKES
Strategic communications consultancy Aurora announces a senior hire to add to its leadership team. Sebastian Stokes joins as director to concentrate on accelerating growth across Aurora’s three practices, focusing on diversification and digital. Stokes has run SHED Communications for five years, a communications consultancy whose clients include the WHO and Pfizer.
Cuttsy+Cuttsy
MATT FERGUSON
Cuttsy+Cuttsy has announced the appointment of Matt Ferguson as creative digital lead, to strengthen the agency’s digital offering to its growing number of clients. Ferguson is experienced in designing apps, delivering web solutions for ecommerce and events companies, working on digital transformation projects through to skills in user experience and analytics.
Hanover Health
JOSIE GODFREY
Hanover Health has appointed former NICE programme leader Josie Godfrey as a senior associate. Godfrey has 12 years’ experience in market access strategy and established the Highly Specialised Technologies programme at NICE. She is currently strategic director for Project HERCULES and a founding co-chair of the EUCOPE Gene and Cell Therapy Working Group.
VMLY&R Health
CHRISTIANNA GORIN
VMLY&R Health has appointed Christianna Gorin as Health Practice Lead and Chief Strategy Officer in North America. Gorin has over 20 years’ experience in healthcare offering strategic vision for HCP global Rx launches on behalf of companies including Lilly, Novartis and Boehringer Ingelheim, and includes work for Pfizer, Merck and PhRMA.
Ogilvy Health
REBECCA CARTER
Healthcare communications agency Ogilvy Health has promoted Rebecca Carter to the newly created role of head of social media. Carter has been working at the agency for seven years, joining from Bupa where she worked as digital managing editor. Since joining Ogilvy Health, she has been key to growing the agency’s full service offering.
Ashfield MedComms
BEVERLY PISARCZYK
Joining the team at Ashfield MedComms is Beverly Pisarczyk, who has been appointed as its new head of client services and promotional strategy in the US. Pisarczyk brings more than 20 years' experience in the medical communications industry to the role, having most recently served as SVP, account strategy at Fallon Medica.
Axon
COLETTE BALAAM
Axon has appointed Colette Balaam as its new managing partner in the US and lead of its New York office. Balaam joins from Readout Health where she was the commercial lead. Previously she was CEO of the US operations of Hive, and has also worked with Virtuoso, where she was a managing director, Edelman and Y&R.
Wilmington Healthcare
TINA WHITE
Wilmington has appointed leading NHS programme director Tina White as a consultant. Tina has over 30 years’ experience in a range of clinical and managerial roles, including programme director at Frimley ICS where she developed its Sustainability and Transformation Plan. During the pandemic, White established a workforce 'bureau' model that was taken up by NHSE.
Onyx Health
ANABEL DAKIN
Newcastle-based Onyx Health has announced the appointment of Anabel Dakin as senior designer, in which role she will have strategic oversight of all aspects of the agency’s creative design work. Dakin has a wealth of design experience, gained from having previously worked on projects for Stonewall, the Premier League, NHS England and the Cystic Fibrosis Trust.
Onyx Health
SUMAN KAUR
In a further addition to the team, Onyx Health has appointed Suman Kaur as senior marketing communications project manager, in which role she will act as strategic lead. Kaur has extensive experience in social media marketing, SEO, web design, analytics and UX. Before joining the team at Onyx, Suman worked for North East agencies Cool Blue and Mediaworks.
Onyx Health
BETH KERRIGAN
Onyx Health has appointed Beth Kerrigan as business and finance manager, with responsibility for managing the company’s operational, financial procedures, client invoicing and budgets. Kerrigan is an AAT qualified accountant with extensive finance experience both in private practice and in-house. Previously she worked at accountancy firms Baldwins and Stephenson Coates.